Literature DB >> 11770389

Do women have more adverse drug reactions?

M Rademaker1.   

Abstract

Up to 5% of all hospital admissions are the result of adverse drug reactions (ADRs). Identifying those factors which may predispose to ADRs is essential for risk management. Amongst the known risk factors for adverse reactions are increasing age, polypharmacy, liver and renal disease as well as being female. Female patients have a 1.5- to 1.7-fold greater risk of developing an ADR, including adverse skin reactions, compared with male patients. The reasons for this increased risk are not entirely clear but include gender-related differences in pharmacokinetic, immunological and hormonal factors as well as differences in the use of medications by women compared with men. Women generally have a lower lean body mass, a reduced hepatic clearance, have differences in activity of cytochrome P450 (CYP) enzymes (40% increase in CYP3A4, varied decrease in CYP2D6, CYP2C19 and CYP1A2), and metabolize drugs at different rates compared with men. Other important factors include conjugation, absorption, protein binding and renal elimination, which may all have some gender-based differences. However, how these differences result in an increased risk of ADRs is not clear. There are pharmacodynamic differences between men and women, seen particularly with cardiac and psychotropic medications. There is no doubt that chlorpromazine, fluspirilene and various antipsychotics appear more effective in women than men for the same dosage and plasma concentration. Similarly, women are at increased risk of QT prolongation with certain anti-arrhythmic drugs compared with men even at equivalent serum concentrations. The mechanisms are unknown. Increasingly the evidence is that idiosyncratic drug reactions, particularly cutaneous reactions, appear to have an immunological etiology. It is possible that gender difference in T cell activation and proliferation account for this as well as the increased prevalence of skin diseases such as systemic lupus erythematosus and photosensitivity. Whatever the mechanism(s), it is important to be aware that gender is a significant factor in ADRs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11770389     DOI: 10.2165/00128071-200102060-00001

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  87 in total

1.  Serum metabolomic profiles suggest influence of sex and oral contraceptive use.

Authors:  Margherita Ruoppolo; Ilaria Campesi; Emanuela Scolamiero; Rita Pecce; Marianna Caterino; Sara Cherchi; Giuseppe Mercuro; Giancarlo Tonolo; Flavia Franconi
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

Review 3.  [Gender aspects in anesthesia : modified approach in research and treatment?].

Authors:  M Schopper; P I Bäumler; J Fleckenstein; D Irnich
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

4.  Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands.

Authors:  Aileen B Dequito; Peter G M Mol; Jasperien E van Doormaal; Rianne J Zaal; Patricia M L A van den Bemt; Flora M Haaijer-Ruskamp; Jos G W Kosterink
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

Review 5.  Predicting risk of adverse drug reactions in older adults.

Authors:  Amanda Hanora Lavan; Paul Gallagher
Journal:  Ther Adv Drug Saf       Date:  2016-02

6.  Gender-Related Differences in the Expression of Organic Cation Transporter 2 and its Role in Urinary Excretion of Metformin in Rats.

Authors:  Yan-Rong Ma; Hong-Yan Qin; Yong-Wen Jin; Jing Huang; Miao Han; Xing-Dong Wang; Guo-Qiang Zhang; Yan Zhou; Zhi Rao; Xin-An Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

Review 7.  [Gender differences in acute and chronic pain conditions. Implications for diagnosis and therapy].

Authors:  M Schopper; J Fleckenstein; D Irnich
Journal:  Schmerz       Date:  2013-09       Impact factor: 1.107

Review 8.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

9.  European Medicines Agency policies for clinical trials leave women unprotected.

Authors:  Maria Teresa Ruiz Cantero; Maria Angeles Pardo
Journal:  J Epidemiol Community Health       Date:  2006-11       Impact factor: 3.710

10.  Age- and gender-related differences in drug utilisation and adverse drug reaction patterns among patients in a coronary care unit.

Authors:  Nitin Subhashchandra Kunnoor; Padmini Devi; Deepak Yogesh Kamath; Naveen Anthony; Jesso George
Journal:  Singapore Med J       Date:  2014-04       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.